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Abstract
Introduction: The objective of this study was to investigate the effects of some clinical and pathological features of prolactinomas on 
tumour behaviour. 
Material and methods: The study included 113 patients with prolactinoma (27 male, 86 female), with a mean age at diagnosis of 34.4 ± 
± 10.0 years (40.3 ± 12.6 in males, 32.6 ± 8.3 in females). Patients were grouped as invasive or non-invasive according to radiological 
imaging findings. Ki-67 levels were evaluated if possible. 
Results: The mean adenoma size (longest dimension) was 38.6 ± 21.6 mm and 10.8 ± 9.4 mm in male and female patients. Pre-treatment 
serum levels of prolactin were defined as mean 1,926 ± 6,662ng/mL in all, 124.8 ± 63.4 and 4,675 ± 10,049ng/mL in the noninvasive and 
invasive groups (p < 0.05). A positive correlation was found between the serum levels of prolactin and tumour size. The rate of patients 
with Ki-67 ≥ 0.03 was 37.5% and 47.8% in the noninvasive and invasive groups. The reduction rates were 60.8% and 80.4% in tumour 
sizes and 81.1% and 93.8% in prolactin level in the noninvasive and invasive groups, respectively, (p < 0.05). 
Conclusions: We found a strong correlation between prolactin levels and invasiveness in male patients compared to females. Ki-67 index 
was not found to have a place in defining the prognosis. (Endokrynol Pol 2014; 65 (3): 210–216)
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Streszczenie
Wstęp: Celem badania była analiza zależności pomiędzy wybranymi danymi klinicznymi i cechami patomorfologicznymi a przebiegiem 
klinicznym u pacjentów z  gruczolakiem przysadki wydzielającym prolaktynę (prolactinoma)/lub z gruczolakiem prolaktynowym przysadki 
Materiał i metody: Do badania włączono 113 pacjentów, u których rozpoznano guzy typu prolactinoma (27 mężczyzn, 86 kobiet). Średni 
wiek pacjentów w momencie rozpoznania wynosił 34,4 ± 10,0 lat (40,3 ± 12,6 u mężczyzn, 32,6 ± 8,3 u kobiet). Na podstawie badań 
obrazowych/badań radiologicznych guzów pacjentów podzielono na dwie  grupy — z gruczolakami inwazyjnymi i gruczolakami niein-
wazyjnymi. Wskaźnik Ki-67 oceniono w tych preparatch, gdzie było to możliwe. 
Wyniki: Średni wymiar gruczolaka (mierzony według najdłuższej osi) wyniósł 38,6 ± 21,6 mm u mężczyzn i 10,8 ± 9,4 mm u kobiet. 
Średnie stężenie prolaktyny w surowicy przed leczeniem wynosiło 1926 ± 6662 ng/ml w całej grupie badanej, 124,8 ± 63,4 w grupie 
guzów nienaciekających i 4675 ± 10049 ng/ml w przypadku guzów naciekających (p < 0,05). Stwierdzono istnienie dodatniej zależności 
pomiędzy stężeniem prolaktyny w surowicy i wymiarem guza. Odsetki pacjentów, u których wartość wskaźnika Ki-67 była duża (≥ 0,03) 
wyniosły odpowiednio 37,5% w grupie guzów nienaciekających i 47,8% w grupie guzów naciekających. W grupie nowotworów nie-
naciekających zmniejszenie wymiarów gruczolaka nastąpiło u 60,8% a zmniejszenie stężenia prolaktyny u 81,1% pacjentów, natomiast 
w grupie guzów naciekających odpowiednie wartości wyniosły 80,4% i 93,8% (p < 0,05). 
Wnioski: U mężczyzn stwierdzono istnienie wyraźnej zależności pomiędzy stężeniem prolaktyny w surowicy a charakterem naciekającym 
guza, czego nie wykazano u kobiet. Wskaźnik Ki-67 nie miał związku z charakterem wzrostu guza. (Endokrynol Pol 2014; 65 (3): 210–216)
Słowa kluczowe: prolactinoma; wzrost nowotworu; naciekanie; wymiary gruczolaka; płeć
Introduction
Pituitary adenomas are the most common form of 
intracranial lesions. The prevalence of pituitary ad-
enomas varies between 5 and 20% in all intracranial 
tumours [1–3]. Prolactinomas are the most common 
cause of pituitary adenomas, accounting for 60% of 
the pituitary adenomas causing clinical manifestations. 
Non-functioning adenomas represent 15%, somatotro-
pinomas 13%, and ACTH-secreting adenomas 6%. The 
majority of prolactinomas are small microadenomas 
that can be treated with dopamine agonists; however, 
they can present different features of biological be-
haviour and are sometimes seen as macroadenomas 
or giant adenoma size. Macroadenomas are identified 
later, with symptoms of visual impairment, headache 
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and hypopituitarism more often seen because of extra-
cellular diffusion [4, 5].
The mechanism and definition of aggressive biologi-
cal behaviour in prolactinomas has not been fully de-
fined. Usually, because of its great size and spread into 
surrounding tissues, an adenoma is defined as invasive 
in imaging modalities. Not all aggressive adenomas 
continue to follow an aggressive course. Although some 
adenomas are quite invasive during diagnosis, they may 
be quickly controlled with therapy, being reduced in 
size and with serum prolactin reduced to normal levels. 
On the other hand, some prolactinomas are unrespon-
sive to treatment, with uncontrolled serum prolactin 
levels and may quickly involve the surrounding tissues, 
despite treatment. Adenomas that are unresponsive to 
surgical or medical therapies are clinically referred to 
as aggressive adenomas [6].
Several histopathological evaluations (cell 
proliferatıon markers or angiogenesis) have been con-
ducted on the early diagnosis of biologically aggressive 
adenomas. The results of these studies based on the 
determinants of cell proliferation are inconsistent with 
the criteria on clinical aggression [6].
Many studies have reported that serum prolactin 
level was correlated with the tumour size and invasive-
ness of the adenoma. Levels of serum prolactin higher 
than 3,300 ng/mL have been reported to be definitive, 
with a specificity of 91% (sensitivity was not mentioned) 
[7]. In another study, the levels of serum prolactin were 
significantly higher in tumours causing cavernous sinus 
invasion [8].
In our study, the aim was to investigate the effects 
of some clinical and pathological features on tumour 
behaviour in prolactinomas and the effects of differ-
ences in tumour behaviour on responses to treatment. 
Material and methods
This study included prolactinoma patients, 61 with 
macroadenomas and 52 with microadenomas, followed 
up at Uludağ University Department of Endocrinology 
and Metabolism. Patients’ demographic characteristics, 
pretreatment plasma prolactin levels at the time of 
diagnosis and sella MR imaging findings, the thera-
pies received and plasma levels of prolactin and sella 
MR imaging findings until the final polyclinic control 
were recorded from the archive files. Similar numbers 
of patients with macroadenomas and microadenomas 
were included for a reliable comparison. According to 
the sella MR imaging findings during the diagnosis, the 
tumours were defined as microadenoma (the longest 
dimension < 1 cm), macroadenoma (the longest di-
mension between 1 and 4 cm) or giant adenoma (the 
longest dimension > 4 cm). The patients were divided 
into two groups as having non-invasive or invasive 
tumour. This grouping considered their stage accord-
ing to Hardy classification and invasion status to the 
cavernous sinuses. [9]. The invasive properties of the 
adenomas were graded using Hardy classification. For 
this purpose, sella base was graded as 1–4 according 
to the degree of destruction; and between A and E, ac-
cording to the degree of suprasellar extension, based on 
the sella MR images [9]. According to the radiological 
findings, tumours of grades 1–2 and stages A–C stages 
were included in the non-invasive group, while those 
of grades 3–4 and stages D–E were classified as invasive. 
The coronal sections on sella MR images were examined 
in detail and persistence or absence of cavernous sinus 
invasion was defined. The adenomas involving 67% 
(two-thirds) of the segment in the cavernous sinus of 
internal carotid artery were defined as cavernous sinus 
invasion and these patients also included in the invasive 
group [6, 10]. In addition, Ki-67 indices were recorded in 
line with the histopathological reports of the operated 
patients in order to evaluate the association of Ki-67 
index with the tumour behaviour (in patients for whom 
Ki-67 levels were measured during histopathological 
evaluation). The patients with a Ki-67 index ≥ 3/100 were 
considered as having highly proliferative properties [7]. 
This study was approved by the Uludağ University, 
Medical Faculty, Bursa Clinical Research Ethics Com-
mittee. All the cases were informed of the aims of the 
study and provided signed written consent. 
SPSS (version 17) was used for statistical analysis. 
Demographic and clinical data was analysed using de-
scriptive statistics (arithmetic mean, standard deviation) 
and percentage. The independent t-test, Kruskal-Wallis 
and Mann-Whitney U analysis of variance were used 
to evaluate means between groups. The chi-square test 
was used for comparison of categorical data between 
groups. Pearson and Spearman correlation analyses 
were used to examine correlation, where appropriate. 
P values < 0.05 were considered statistically significant.
Results
The mean age at the time of diagnosis was 34.4 ± 10.0 
(16–70) years in 113 patients (27 males, 86 females). The 
mean age at diagnosis was 40.3 ± 12.6 (19–70) among 
male and 32.6 ± 8.3 (16–60) among female patients. 
The mean of adenoma sizes (longest dimension) was 
17.9 ± 18.1 (2–80) mm overall, 38.6 ± 21.6 (3–80) mm 
in male and 10.8 ± 9.4 (2–45) mm in female patients. 
The rate of operated patients was 44.3% overall and 
85.2% among male patients. Male and female patients 
showed significant differences in terms of age at di-
agnosis, mean adenoma sizes and rate of operated 
patients (Table I).
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There were 68 patients (60.2%) in the non-invasive 
and 45 patients (39.8%) in the invasive group. The rate 
of invasive pituitary adenoma was significantly higher 
in male than female patients (81.5% vs. 26.7%) (Table I). 
The mean age at diagnosis was 32.3 ± 7.9 (16–54) years, 
and male to female ratio was 5/63 in the non-invasive 
group, compared to 37.6 ± 12.0 (18–70) years and 22/23 
in the invasive group. When the mean ages and gender 
ratios were compared, a statistically significant differ-
ence was found between the invasive and non-invasive 
groups. However, the subgroups showed no statistically 
significant difference in gender ratios between the in-
vasive and non-invasive groups (Table II). 
The mean pre-treatment longest diameter of adeno-
mas was 27.8 ± 53.4 mm (2–80 mm) overall; 20.7 ± 22.9 mm 
(2–25 mm) in the non-invasive group; and 38.4 ± 79.0 mm 
(10–80 mm) in the invasive group. The mean pre-treat-
ment levels of serum prolactin were 1,926 ± 6,662 ng/mL 
(650.8 ng/mL after the 5th percentiles were excluded) 
overall, compared to 124.8 ± 63.4 ng/mL in the non-
invasive group and 4.6 ± 10.0 ng/mL (2.9 ng/mL after 
the 5th percentiles were excluded) in the invasive group. 
Table I. General characteristics of the patients according to gender 
Tabela I. Charakterystyka grupy badanej w zależności od płci
Total Male Female p
Number of patients (n) 113 27 86
Age (years) 40.8 ± 10.1 45.1 ± 12.1 39.5 ± 9.0 0.011
Age at diagnosis (years) 34.4 ± 10.0 40.3 ± 12.6 32.6 ± 8.3 < 0.01
Adenoma size [mm] 17.9 ± 18.1 38.6 ± 21.6 10.8 ± 9.4 < 0.01
Macroadenoma (%) 54.0 85.2 44.2 < 0.01
Giant adenoma (%) 14.2 48.1 3.5 < 0.01
Invasive (%) 39.8 81.5 26.7 < 0.01
Operated rate (%) 44.3 74.1 34.9 < 0.01
The rates of macroadenomas contain the giant adenomas. p values  associated with the male and female groups
Table II. Ages at diagnosis, adenoma size, prolactin levels, Ki-67, high Ki-67 and operated patient rates in noninvasive and 
invasive groups with gender
Tabela II. Wiek pacjentów w momencie rozpoznania, wymiar guza, stężenie prolaktyny, wskaźnik Ki-67, odsetek przypadków 
ze zwiększonym wskaźnikiem Ki-67 oraz odsetek pacjentów operowanych w grupie guzów naciekających i w grupie bez cech 
naciekania w zależności od płci
Total Noninvasive Invasive p
Number of patients (n) 113 68 45
Age at diagnosis (years) 
Male 
Female
34.4 ± 10.0 
40.3 ± 12.6 
32,6 ± 8,3
32.3 ± 7.9 
40.4 ± 9.5 
31.6 ± 7.5
37.6 ± 12.0 
40.3 ± 13.4 
35.1 ± 10.1
0.011 
NS 
NS
Adenoma size [mm]  
Male 
Female
17.9 ± 18.1 
38.6 ± 21.6 
10.8 ± 9.4
6.8 ± 3.8 
9.2 ± 9.1 
6.6 ± 3.1
34.7 ± 18.4 
45.3 ± 17.5 
23.1 ± 11.1
< 0.01 
< 0.01 
< 0.01
Prolactin level [ng/mL]  
Male 
Female
1,927 ± 6,662 
6,818 ± 12,399 
402 ± 1,403
124 ± 63 
138 ± 68 
123 ± 63
4,675 ± 10,049 
8,576 ± 13,446 
1,147 ± 2,584
< 0.01 
< 0.01 
< 0.01
Ki-67 index means 
Male 
Female
0.03 ± 0.02 
0.03 ± 0.02 
0.03 ± 0.02
0.03 ± 0.02 
0.09* 
0.02 ± 0.02
0.03 ± 0.03 
0.02 ± 0.02 
0.03 ± 0.02
NS 
NS 
NS
High Ki-67 rates (%) 
Male 
Female
45.1 
53.8 
38.9
37.5 
100.0* 
28.6
47.8 
50.0 
45.5
NS 
NS 
NS
Operated rates (%) 
Male 
Female
44.3 
74.1 
34.9
17.6 
20.0 
17.5
84.4 
86.4 
82.6
< 0.01 
0.013 
< 0.01
*Only one patient; p values  associated with the noninvasive and invasive groups
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The longest tumour diameter values and serum prol-
actin levels were significantly different between the 
non-invasive and invasive groups (Table II). On the 
sella MRI imaging taken at diagnosis, microadenoma 
was identified in 46%, macroadenoma (including gi-
ant adenomas) in 54%, and giant adenoma in 14.2% 
of the patients. Of the macroadenomas, 37.2% were in 
the non-invasive and 62.8% in the invasive group. The 
incidence of cavernous sinus invasion was 65.1% among 
the invasive group. Furthermore, a positive correlation 
was found between the pre-treatment levels of serum 
prolactin and tumour size. The correlation coefficient 
was 0.805 between log10 values of the prolactin levels 
(ng/mL) and tumour size (mm) (Fig. 1).
Of the 113 patients, 50 were operated upon. There 
was a secondary operation in three patients following 
recurrence. Of the 50 operated patients, 12 (24%) were 
in the non-invasive and 38 (76%) were in the invasive 
group. The difference between two groups in terms of 
the rates of operated and non-operated patients was 
statistically significant, although the patients operated 
upon were not associated with tumour behaviour, due 
to lack of sufficient information in the archival files 
(Tables I, II).
When the 31 patients studied with Ki-67 indices 
were examined histopathologically, high proliferation 
values (Ki-67 ≥ 0.03) were found in 14 (45.2%) patients, 
while Ki-67 indices < 0.03 were defined in 17 (54.8%) 
patients. Mean age at diagnosis was 38.14 ± 10.0 
(n = 14) in the high-Ki-67 group and 32.76 ± 7.5 (n = 17) 
in the low-Ki-67 group. The proportion of patients with 
Ki-67 ≥ 0.03 was 37.5% in the non-invasive group and 
47.8% in the invasive group. The invasive group had an 
average Ki-67 value of 0.031 (0.001–0.085), whereas the 
non-invasive group had 0.033 (0.007–0.097) (p: 0.718). 
The difference between two groups was not found to be 
statistically significant (Table II). Three patients (37.5%) 
in the invasive group and 11 patients (47.8%) in the 
non-invasive group were categorised as having high 
Ki-67 index. The incidence of cavernous sinus invasion 
was 52.9% in the low-Ki-67 group, compared to 50.0% 
in the high-Ki-67 group.
When the responses to surgical and dopamine 
agonist therapy were evaluated, rates of tumour re-
duction were 60.8% and 80.4%, and 81.1% and 93.8% 
in prolactin level within the non-invasive and invasive 
groups, respectively. The percentage reduction in prol-
actin levels and adenoma size were significantly higher 
in the invasive adenomas compared to non-invasive 
(Table III). Reduction in tumour size and prolactin level 
were 75.19% and 90.96%, respectively, in the low Ki-67 
group, compared to 86.36% and 88.16% in the high 
Ki-67 group (p = 0.561, p: 0.922). When the responses 
to the treatment were evaluated in terms of the Ki-67 
cell proliferation indices, no statistically significant dif-
ference was found between the groups with high and 
low indices in terms of the change in tumour size or 
prolactin level (Table IV).
Discussion
Prolactinomas are by far the most common type of tumours, 
representing 60% of pituitary adenomas [3]. These are 
often benign, but may present differences in terms of 
tumour size and treatment responses at the time of 
diagnosis due to their different biological behavioural 
characteristics. In general, prolactin-secreting pituitary 
adenomas give a very good response to dopamine ago-
nists and both provide improvement of hypogonadism 
symptoms by enabling serum prolactin to return to 
normal levels and eliminate compression symptoms 
by reduction of the adenoma size. In rare cases, pro-
Figure 1. Correlation between pretreatment prolactin level and 
longest tumour diameter
Rycina 1. Zależność pomiędzy stężeniem prolaktyny i największym 
wymiarem guza przed leczeniem
Table III. Response to treatment in noninvasive and invasive 
groups 
Tabela III. Odpowiedź na leczenie w zależności od charakteru 
guza (nieinwazyjny/inwazyjny)
Noninvasive 
(n = 68)
Invasive  
(n = 45)
p
Tumour Size
Before Treatment [mm] 20.7 ± 22.9 38.4 ± 79.0
After Treatment [mm] 2.33 ± 2.3 7.49 ± 13.5
Change rate (%) 60.8 80.4 0.02
Prolactin Level
Before Treatment [ng/mL] 124 ± 63 4,675 ± 10,049
After Treatment [ng/mL] 6.8 ± 3.8 34 ± 18
Change rate (%) 81.1 93.8 < 0.01
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lactinomas are resistant to treatment with dopamine 
agonist and these desired outcomes are not achieved. 
In this study, mean serum prolactin levels were 
38.4 ± 79.0 and 4,675.8 ± 10,049.2 ng/mL in the non-
invasive and invasive groups, respectively. There was 
a statistically significant positive correlation between 
the pre-diagnosis prolactin levels and tumour size 
(R: 0.805, p < 0.01). As expected, these findings show 
serum prolactin level to be an important factor in the 
definition of tumour behaviour. In a study by Lundin et al. 
[11] with 115 hypophysis macroadenoma cases, the size 
and invasiveness of the tumours were evaluated from 
MR imaging with hormonal activity, and the strongest 
correlation was found between the tumour size and 
prolactin level in the patients with prolactinoma. In 
a study by Raverto et al. [12], 91 operated prolactinoma 
patients were evaluated and the mean preoperative 
prolactin levels were found to be 262 ± 532 and 
1,633 ± 1,890 µg/L in the non-invasive and invasive adeno-
mas, respectively. In a study by Calle-Rodrigue et al. [7], 
the mean preoperative prolactin levels were 705 ng/mL in 
the invasive and 141 ng/mL in the non-invasive prolac-
tinomas. In that study, the cut-off value of 3,300 ng/mL 
for the serum prolactin level was reported to have 
a sensitivity of 91% in the definition of the invasive 
prolactinomas. In our study, when cases with a serum 
prolactin level higher than 3,300 ng/mL were examined 
(n:8), all were in the invasive adenoma group. Of pa-
tients with a lower serum level of prolactin, 61 were in 
the non-invasive and 32 in the invasive group. When 
the cut-off value was taken as 400 ng/mL, sensitivity 
was calculated as 70% and specificity as 100%.
In our study, the mean tumour size was 38.6 ± 21.6 
(3–80) mm in the male patients and 10.8 ± 9.4 (2–45) 
mm in the female patients. The rates of invasive pitui-
tary adenomas, macroadenomas and giant adenomas 
were significantly higher in the male than in the fe-
male patients. The age of diagnosis was significantly 
higher in the male compared to the female patients. 
In this study, 81% (13/16) of the giant adenomas were 
in the male patients. Delgrange et al. [13] examined 
the association between tumour size and prolifera-
tive properties according to gender (96 prolactinoma 
cases; 45 males and 51 females). Basal prolactin levels 
and tumour diameters were higher in the males than 
females (p < 0.001). In a retrospective study by Nish-
ioka et al. [14] with 51 prolactinoma patients (16 males, 
35 females), large tumours were predominant in the 
male patients, and these patients were more likely to 
develop cysts and haemorrhaging. Furthermore, the 
correlation between prolactin level and tumour size was 
less significant among male than female patients, but 
the difference was eliminated after patients with cystic 
and haemorrhagic masses were excluded. The results 
from our study indicate, as expected, that male gender is 
a determinant factor in tumour properties. However, it 
is unclear whether the difference seen in male patients 
regarding the diameter and invasiveness of the tumour 
is caused by a difference in the tumour formation or by 
a later diagnosis in male patients.
The age of diagnosis in our patients was significant-
ly higher for invasive than non-invasive adenomas. 
However, the rates of male patients were also higher 
in the invasive group and, as mentioned previously, 
the association of male gender with invasiveness and 
size of tumour is widely accepted. It was reported by 
Delgrange et al. [13] that age at diagnosis and symptom 
duration was not associated with prolactin level and 
tumour size. Another study by the same author inves-
tigated the effect of age on male prolactinoma patients; 
basal prolactin levels (3.051 ± 4.151 vs. 3.365 ± 4.949 µ/L) 
and the mean tumour diameter (30 ± 16 vs. 25 ± 13 mm) 
were found to be similar in nine elderly and ten young 
patients [15]. In a study by Raverot et al. [12], the mean 
preoperative age was 33.4 ± 10.9 in the non-invasive 
group (n: 61; 64.9%), 43.3 ± 11.5 in the invasive group 
(n: 22, 23.4%) and 51.5 ± 10.4 in the invasive-aggressive 
group (n: 11; 11.7%). However, the mean ages of the 
subgroups according to gender were not given in that 
study, and there were more male patients with inva-
sive adenomas compared to the non-invasive group. 
Accordingly, age is not an independent factor in the 
invasiveness or size of tumours and age-related dif-
ferences are associated with older age at diagnosis in 
the male patients.
Table IV. Response to treatment in low and high Ki-67 ratio 
groups
Tabela IV. Odpowiedź na leczenie w zależności od wartości 
wskaźnika Ki-67 (mały/duży)
Ki-67 < % 3  
(n = 17)
Ki-67 ≥ % 3  
(n = 14)
p
Tumour Size
Before Treatment 
[mm]
26.0 ± 16.5 27.9 ± 18.2
After Treatment 
[mm]
8.3 ± 15.1 6.2 ± 15.6
Change rate (%) 75.1 86.3 NS
Prolactin Level
Before Treatment 
[ng/mL]
3,465 ± 7,075 4,744 ± 14,269
After Treatment 
[ng/mL] 
29 ± 38 49 ± 107
Change rate (%) 88.9 83.8 NS
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In the WHO classification of endocrine tumours, 
pituitary adenomas with Ki-67 index and p53 immune 
reactivity > 3% are classified as atypical adenomas. In 
a study by Thapar et al. [16], Ki-67 values were evalu-
ated in 37 non-invasive adenomas, 33 invasive adeno-
mas and seven primary hypophysis carcinomas, and the 
mean values were 1.3%, 4.6% and 11.9%; respectively 
(p < 0.01). In that study, Ki-67 index with a cut-off value 
> 3% was reported to have a sensitivity of 97% and 
specificity of 73% in differentiation between invasive 
and non-invasive tumours. On the other hand, in the 
study by Delgrange et al. [13], no significant difference 
was identified between invasive and non-invasive 
groups in terms of Ki-67 index values in 45 male and 
51 female patients with prolactinomas. In a study by 
Scheithauer et al. [17] with 153 hypophysis tumour 
cases, Ki-67, PCNA indices and p63 expressions of tu-
mour tissue were evaluated; no significant difference 
was found between the non-invasive and invasive tu-
mours. In a study by Paek et al. [18] with 44 hypophysis 
macroadenoma cases, a high Ki-67 index was correlated 
with visual field defect and rates of tumour recurrence, 
while there no statistical difference regarding tumour 
diameter, tumour degree, Hardy classification and 
cavernous or sphenoid sinus invasion.
In our study, evaluation of Ki-67 index values could 
be carried out in pathological materials of 31 patients. 
In the evaluation, the mean Ki-67 indices in the non-
invasive and invasive prolactinomas were very similar, 
at 0.033 ± 0.03 and 0.031 ± 0.02, respectively. Ki-67 index 
was higher than 3% in three patients (37.5%) in the inva-
sive group and 11 patients (47.8%) in the non-invasive 
group. According to these results, Ki-67 index was not 
a prognostic determinant in the prolactinoma patients.
The objective of defining the properties of tumour 
behaviour is to identify treatment unresponsiveness 
and the risk of recurrence. A decrease of less than 50% in 
prolactin level or tumour size compared to the baseline 
values is considered as unresponsive [19]. In our study, 
treatment responses were evaluated by examination of 
the changes in the basal and final prolactin levels and 
the percentage change in the adenoma size. Accord-
ingly, no significant difference was found between 
patients with a Ki-67 index ≥ 3% and those with a low 
Ki-67 index, in terms of changes in the prolactin levels 
and adenoma sizes. In a study by Wu et al. [20], a mean 
decrease of 93% in the tumour diameter was reported 
at 37 months follow-up of bromocriptine therapy in 
giant prolactinomas. In a study by Delgrange et al. [21] 
with 122 macroprolactinoma cases, the need for higher 
doses of cabergoline was reported in male patients and/ 
/or invasive tumours, but normalisation in the prolactin 
level was reported in 94% of patients. 
The results from our study also indicate that the 
type of invasive tumour or high cellular proliferation 
does not negatively affect treatment outcomes; even 
the decrease in prolactin levels and adenoma sizes was 
found to be higher in the invasive tumours. 
These findings show that treatment response is not 
poorer in the presence of invasion in prolactinomas, 
and that proportionally better outcomes may even be 
obtained. These rates do not suggest curative outcomes 
in the long term, but indicate that the treatment ap-
proach is not necessarily different in invasive tumours. 
The treatment response in prolactinomas is thought 
to be more closely related to changes in cellular D2 
receptors [22]. 
Conclusions
In this study, as indicated by previous studies, 
a strong correlation was found between prolactin lev-
els and the size and invasiveness of tumours. The size 
and invasiveness of the tumours were significantly 
higher in male compared to female patients. How-
ever, no definitive role was identified for prolactin 
levels, tumour sizes, invasiveness or gender in terms 
of treatment response. 
In our study, the mean of Ki-67 indices were found 
to be similar in invasive and noninvasive groups. Fur-
thermore, Ki-67 indices were not found to be related 
to treatment response. Accordingly, in determining the 
behaviour of the tumour in prolactinomas, Ki-67 index 
cannot play a decisive role.
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